Deliver to United Kingdom
0

HPLC column NUCLEODUR ® Phenyl-Hexyl, 5 µm, 150 mm, 4.6 mm

£ 696.60*

*Prices plus VAT plus shipping costs

£ 835.92*

*incl. VAT, plus shipping costs

HPLC column NUCLEODUR ® Phenyl-Hexyl, 5 µm, 150 mm, 4.6 mm

Order number: 34PC.1

Part number: AC100007092

In Stock

Price Breakdown

1

6

24

Intended for structured formulation workflows, the Hplc Column Nucleodur ® Phenyl-Hexyl, 5 μm, 150 mm, 4.6 mm offers a unique reversed phase (RP) separation principle that combines both π-π interactions and hydrophobic interactions. With a particle size of 5 μm and a specific surface area of 340 m²/g, it ensures efficient separation of aromatic and unsaturated compounds such as antibiotics, pharmaceutical products, steroids, and even those suitable for LC-MS applications. Its endcapped structure and pH stability range of 1.0-10.0 make it compatible with acetonitrile-water eluents and stable up to 60°C. Furthermore, its pressure stability of 600 bar and low bleeding characteristics contribute to its suit

  • Category: Separation columns for HPLC
  • Phase: Phenyl-Hexyl
  • Particle type: Fully porous particles (FPP)
  • Eluent in column: Acetonitrile - Water
  • L x Ø internal (column): 150 x 4.6 mm
  • Surface chemistry: Phenylhexyl modification
  • Application Database (Macherey-Nagel): HPLC
  • Column type: HPLC column
  • Pore size: 110 Å
  • Endcapped: yes
  • Column shape: Analytical separation column
  • Pressure stability: 600 bar
  • Temperature stability: 60 ° C
  • USP listing: L11
  • Pore volume: 0.9 ml/g
  • Column volume: 2.5 ml
  • Specific surface according to BET: 340 m²/g
  • Separation principle: Reversed phase (RP)
  • pH stability: 1,0-10,0
  • Recommended application(s): Antibiotics Aromatic and unsaturated compounds Suitable for LC-MS Pharmaceutical products Especially for polar compounds Steroids
  • Interactions / retention mechanism: π-π and hydrophobic
  • Particle size: 5 µm
allied chemi
  • secure-payment
  • visa
  • american-express
  • master-card

© 2026 Copyright. All Rights Reserved.